NASDAQ: CNTX
Context Therapeutics Inc.CIK 0001842952 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (WCN 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade CNTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 5, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 12,529,567 | 7,830,544 | 19,544,866 | 11,293,535 |
| General and administrative | 2,437,924 | 1,927,818 | 4,766,424 | 3,993,970 |
| Loss from operations | (14,967,491) | (9,758,362) | (24,311,290) | (15,287,505) |
| Interest income | 418,663 | 903,772 | 938,802 | 1,862,289 |
| Other income (expense) | (9,598) | 27,080 | 133,490 | 20,445 |
| Net loss | (14,558,426) | (8,827,510) | (23,238,998) | (13,404,771) |
| Net loss per common share, basic and diluted | (0.15) | (0.09) | (0.24) | (0.14) |
| Weighted average shares outstanding, basic and diluted | 95,183,718 | 95,186,935 | 95,183,718 | 95,186,935 |
Condensed Consolidated Balance Sheets
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 42,990,371 | 65,995,228 |
| Prepaid expenses and other current assets | 2,828,491 | 2,358,474 |
| Total current assets | 45,818,862 | 68,353,702 |
| Property and equipment, net | 74,068 | 29,656 |
| Operating lease right-of-use lease asset | 241,224 | 110,410 |
| Total assets | 46,134,154 | 68,493,768 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 3,288,209 | 2,532,887 |
| Accrued expenses and other current liabilities | 4,428,902 | 5,375,090 |
| Operating lease liability current | 167,468 | 112,064 |
| Total current liabilities | 7,884,579 | 8,020,041 |
| Operating lease liability non-current | 77,524 | — |
| Total liabilities | 7,962,103 | 8,020,041 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.001 par value; 300,000,000 and 200,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 91,879,177 shares issued and outstanding at June 30, 2026 and December 31, 2025 | 91,879 | 91,879 |
| Additional paid-in capital | 192,222,479 | 191,285,157 |
| Accumulated deficit | (154,142,307) | (130,903,309) |
| Total stockholders' equity | 38,172,051 | 60,473,727 |
| Total liabilities and stockholders' equity | 46,134,154 | 68,493,768 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (23,238,998) | (13,404,771) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Acquired in-process research and development charge | 6,500,000 | — |
| Share-based compensation expense | 937,322 | 682,831 |
| Depreciation and amortization expense | 11,334 | 8,120 |
| Reduction in the carrying amount of operating lease right-of-use asset | 70,244 | 52,737 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (470,017) | 34,972 |
| Accounts payable | 755,322 | 958,960 |
| Accrued expenses and other current liabilities | (2,946,188) | 855,651 |
| Operating lease liability | (68,130) | (52,061) |
| Net cash used in operating activities | (18,449,111) | (10,863,561) |
| Cash flows from investing activities: | ||
| Acquired in-process research and development | (4,500,000) | — |
| Purchase of property and equipment | (55,746) | (33,948) |
| Net cash used in investing activities | (4,555,746) | (33,948) |
| Cash flows from financing activities: | ||
| Payment of offering costs from the sale of common stock from ATM facility | — | (15,268) |
| Net cash used in financing activities | — | (15,268) |
| Net decrease in cash and cash equivalents | (23,004,857) | (10,912,777) |
| Cash and cash equivalents at beginning of period | 65,995,228 | 94,429,824 |
| Cash and cash equivalents at end of period | 42,990,371 | 83,517,047 |
| Supplemental disclosure of non-cash activities: | ||
| Right-of-use asset obtained in exchange for lease obligation | 201,058 | — |
| Acquired in-process research and development charge included in accrued expenses | 2,000,000 | — |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗